目的 建立測定胎盤灌流液中格列苯脲濃度的高效液相色譜（HPLC）檢測方法。方法 采用的色譜柱為Symmetry Shield RP C18（150 mm×4.6 mm，5 μm），柱溫40℃，流動相為NaH2PO4緩沖鹽（25 mmol/L，pH值5.2）︰乙腈=1︰1；內標為格列齊特，流速1.0 mL/min，檢測波長228 nm，采用液-液萃取預處理方法測定胎盤灌流液中格列苯脲的濃度。 結果 格列苯脲濃度線性范圍為2.0～25.0 μg/mL，線性方程為：y=0.226x+0.002，r=0.999 9 （n=6），日內相對標準偏差（RSD）＜3.1%，日間RSD＜9.5%，方法學回收率為95.32%～103.35%。 結論 HPLC檢測方法靈敏、簡便，可用于胎盤灌流液中格列苯脲濃度的檢測。
目的 建立柱前衍生化反相高效液相色譜-熒光檢測法測定血漿中同型半胱氨酸（Hcy）濃度的方法。 方法 以tris-(2-carboxylethyl)-phosphine hydrochloride （TCEP）為還原劑，以7-fluorbenzo-2-oxa-1,3-diazole-4-sulfonate （SBD-F）為衍生劑，色譜柱為Xterra RP18柱，柱溫35℃，流動相為甲醇︰磷酸二氫鈉緩沖液（pH值3.0）=3︰97，激發波長380 nm，發射波長510 nm，外標法定量。 結果 Hcy濃度在1.95～125 ?mol/L范圍內線性關系良好（r=0.999 8）。日內和日間相對標準偏差均＜7%，方法回收率為103.2%～111.9%。 結論 此方法準確、靈敏、快速，是一種適合于實驗室研究和臨床檢測血漿中Hcy濃度的方法。
ObjectivesTo systematically review the efficacy and safety of escitalopram in the prevention of post-stroke depression (PSD).MethodsPubMed, The Cochrane Library, CBM, WanFang Data, VIP and CNKI databases were electronically searched to collect randomized controlled trials (RCTs) on escitalopram in preventing PSD from inception to March 2019. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software.ResultsA total of 6 RCTs involving 891 patients were included. The results of meta-analysis showed that: compared with the control group, the escitalopram group could reduce the incidence of PSD (RR=0.55, 95%CI 0.31 to 0.98, P=0.04). In addition, there was no statistical difference between escitalopram group and control group in rate of adverse events (P≥0.05).ConclusionsCurrent evidence shows that escitalopram can reduce the incidence of PSD without increasing the incidence of adverse reactions. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.